All posts

November 7, 2026

What does Altis Labs, which received a $25 million investment, do?

What does Altis Labs, which received a $25 million investment, do?
  • Investment: $25 million
  • Round: Series A
  • Investors: OrbiMed, Qiming Venture Partners USA, Cancer Breakthrough Fund, Innovation Endeavors, Benchstrength, Fusion Fund
  • Founders: Felix Baldauf-Lenschen
  • Website: altislabs.com

What does Altis Labs do?

Founded in 2019 by Felix Baldauf-Lenschen.

The Canada-based company develops artificial intelligence for oncology clinical trials.

It analyzes medical images used in clinical trials of cancer drugs with artificial intelligence.

The model called IPRO generates predictions about patients' survival based on routine radiology images taken during trials.

The model doesn't just look at whether the tumor is shrinking; it correlates image data with the long-term outcomes of patients.

The company's current scale

It offers the technology for use in biopharma companies' clinical trials from Phase 1 to Phase 4.

The aim is to determine earlier if a drug is truly effective compared to existing methods.

Investment round

Altis Labs secured a $25 million investment in a round led by OrbiMed and Qiming Venture Partners USA. The round occurred at the Series A stage.

Where is Altis Labs headed?

2019 Founded
  • Based in Canada
  • Founded by Felix Baldauf-Lenschen
Today IPRO Model
  • Survival prediction from radiology images
  • In Phase 1-Phase 4 clinical trials
Next Expansion
  • Extending models to different cancer types
  • Scaling with global biopharma companies

Startup Doctor's comment

This company isn't developing drugs. It reads existing images to determine earlier if a drug works or not. So the product is not a molecule, but a decision speed.

Notice where the value comes from: the data already existed. Radiology images were routinely taken in clinical trials but no one was extracting these insights from them. No new resource was created; the unread part of the existing resource was read.

This pattern often works in heavily regulated sectors like healthcare, insurance, logistics. Because those industries already collect a lot of data legally, but they save it for record-keeping, not decision-making.

Do this this week: list the data your customer already generates when using your product. Then ask one question— which of these could make them reach a decision earlier?


Source: webrazzi — Altis Labs, developing AI for oncology and clinical trials, received a $25 million investment


FAQs

Who is the founder of Altis Labs?

The company was founded in 2019 by Felix Baldauf-Lenschen.

What does Altis Labs do?

A Canada-based artificial intelligence company. It aims to determine earlier and more accurately than current methods whether cancer drugs are truly effective on patients, by analyzing medical images used in clinical trials.

What is IPRO?

An artificial intelligence model developed by the company. It analyzes radiology images routinely taken during clinical trials to predict patient survival. It aims to detect treatment effects earlier that traditional imaging methods may overlook.

Which investors participated in Altis Labs' round?

The Series A round was jointly led by OrbiMed and Qiming Venture Partners USA. Innovation Endeavors, Benchstrength, Fusion Fund, and Cancer Breakthrough Fund participated in the round.

How will Altis Labs use the investment?

They announced plans to use it to expand AI models to different cancer types, scale commercial applications with global biopharma companies, and popularize AI-enabled endpoints in oncology clinical trials.


If you want to raise funds, too

I explain what you need to know before facing investors in the free training.

Ready to take your startup up a level?

See the Ebook ($6)